Skip to search formSkip to main contentSkip to account menu

tanibirumab

A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Monoclonal Antibodies

Narrower (1)

TTAC-0001
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
Background VEGF is a highly selective mitogen that serves as the central regulator of tumor angiogenesis by mediating endothelial… 
2017
2017
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
SummaryBackground Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We… 
2017
2017
A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM).
e13522Background: Treatment of recurrent GBM remains a challenge. The VEGF signal transduction pathway is upregulated in GBM. We… 
2017
2017
ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA…
2015
2015
Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.
2522 Background: Tanibirumab is a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR-2… 
2014
2014
Tanibirumab, a Novel Anti-Vascular Endothelial Growth Factor Receptor-2 Monoclonal Antibody, Inhibits Angiogenesis and Tumor Growth in Colorectal and Glioma Preclinical Models
2013
2013
Intravitreal tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, partially suppresses and regresses laser-induced choroidal neovascularization in a…
PURPOSE The study investigated the effect of intravitreally administered tanibirumab, a fully human monoclonal antibody against… 
2012
2012
Development of Tanibirumab TM , anti-KDR neutralizing fully human antibody and next generation DIG-bodies TM and PIG-bodies TM
  • J. Yoo
  • 2012
  • Corpus ID: 113322280
Review
2011
Review
2011
Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)